Learn More Learn More Collaboration with Mayo Clinic Adaptive Phage Therapeutics enters agreement with Mayo Clinic to commercialize a phage susceptibility test Learn More Learn More Precision Superbug Therapy Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. Learn More Learn More Success Story In 2016 APT's approach achieved its first in-human success with the rescue of a critically ill MDR infected patient: Tom Patterson, multi-drug resistant Acinetobacter baumannii survivor Learn More Phage are the most prolific bacterial killers on Earth Watch the Video Learn More PhageBank

PhageBank is a large and dynamically growing collection of phage that attack specific targeted bacteria

Learn More

The Diminishing Effectiveness of Antibiotics

This graphic shows the introduction of new classes of antibiotics, and the emergence of resistance to those drugs. Antibiotics have always been accompanied by the appearance of bacterial resistance. This cycle of introducing a new drug only to have bacteria evolve resistance to it is the pattern that PhageBank™ promises to break

Company Story

In 2003, as multi-drug resistant (MDR) bacteria was starting to pose a serious international health risk, National Institutes of Health (NIH) scientist Carl R. Merril, MD, published a pivotal article that outlined prior limitations of phage therapy and suggested concepts that have emerged as the modern approach. In 2010, the Biological Defense Research Directorate (BDRD) of the US Navy began an initiative to explore Dr. Merril’s concepts as a potential way to deal with biodefense threats associated with MDR superbugs. In 2016 this approach achieved a significant milestone with the successful rescue of Tom Patterson, a critically ill A. baumannii infected patient. Tom Patterson’s case was immediately followed by numerous additional patient cases. In response for the need to translate the Navy’s phage research into a commercially available therapy, Adaptive Phage Therapeutics (APT) was founded by Dr. Merril and his son Greg Merril. The company acquired world-wide exclusive rights to BDRD’s phage technology and began efforts to optimize precision phage therapy for rapid, cost effective, clinical adoption.

APT Receives DoD Award for Development of COVID-19 Vaccine APT Receives DoD Award for Development of COVID-19 Vaccine August 19, 2020 GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate vaccine candidates in Phase 1 clinical trials. APT is the only biotechnology company with a phage-based COVID-19 vaccine program projected to enter clinical trials in 2020. GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate vaccine candidates in Phase 1 clinical trials. APT is the only biotechnology company with a phage-based COVID-19 vaccine program projected to enter clinical trials in 2020. Read full article Mayo Clinic as Lead Investor in Convertible Note Financing Mayo Clinic as Lead Investor in Convertible Note Financing August 5, 2020 Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round. Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round. Read full article APT featured in Netflix Series APT featured in Netflix Series August 2, 2020 APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe. APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe. Read full article APT and John Haverty featured in the Boston Globe APT and John Haverty featured in the Boston Globe July 10, 2020 For scientists, clinical trials like these are a first try. For participants, they are often a last hope. At the brink of giving up, John Haverty turned to internet research. He was aware of phage treatment [the therapeutic use of bacteriophages to treat bacterial infections like Haverty’s], and he happened across Maryland-based Adaptive Phage Therapeutics. For scientists, clinical trials like these are a first try. For participants, they are often a last hope. At the brink of giving up, John Haverty turned to internet research. He was aware of phage treatment , and he happened across Maryland-based Adaptive Phage Therapeutics. Read full article Phage-based vaccines Phage-based vaccines June 10, 2020 Phage-based vaccines offer significant potential benefits by establishing a platform approach with the ability to quickly adjust the vaccine in response to mutations in the coronavirus. Additionally, phage-based vaccines are self-adjuvanted, meaning they automatically activate and boost immune response, with the ability to display multiple antigens. The therapeutic use of phage in humans is well understood and has a favorable safety profile. “A vaccine against COVID-19 will be a critical enabler to protect our service members and the American people. [APT's] research contract will expedite prospective efforts to deliver a safe and effective phage-vaccine."Thomas Dunn, Acting Program ManagerNaval Advanced Medical Development, Phage-based vaccines offer significant potential benefits by establishing a platform approach with the ability to quickly adjust the vaccine in response to mutations in the coronavirus. Additionally, phage-based vaccines are self-adjuvanted, meaning they automatically activate and boost immune response, with the ability to display multiple antigens. The therapeutic use of phage in humans is well understood and has a favorable safety profile. “A vaccine against COVID-19 will be a critical enabler to protect our service members and the American people. research contract will expedite prospective efforts to deliver a safe and effective phage-vaccine."Thomas Dunn, Acting Program Manager
Naval Advanced Medical...
Read full article
Collaboration with Mayo Clinic Collaboration with Mayo Clinic June 9, 2020 GAITHERSBURG, Md.--Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Laboratories (MCL). The PST will enable rapid identification of patient-specific precision therapy for challenging bacterial infections, including, but not limited to, those that are antimicrobial resistant (AMR) or complicated with biofilms. GAITHERSBURG, Md.--Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Laboratories (MCL). The PST will enable rapid identification of patient-specific precision therapy for challenging bacterial infections, including, but not limited to, those that are antimicrobial resistant (AMR) or complicated with biofilms. Read full article

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google